Wealth Enhancement Advisory Services
COGT icon

Wealth Enhancement Advisory Services’s Cogent Biosciences COGT Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-5,541
Closed -$215K – 4262
2026
Q2 		$215K Buy
+5,541
New +$194K ﹤0.01% 3519

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Emerald Advisers
Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Emerald Mutual Fund Advisers Trust
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.45B AUM 70.46% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $109B AUM 51.53% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Wealth Enhancement Advisory Services's COGT Position: Q3 2026 in Review

Wealth Enhancement Advisory Services sold out of Cogent Biosciences (COGT) in Q3 2026, closing a stake of 5,541 shares — an estimated $215K sold.

Wealth Enhancement Advisory Services first reported a position in COGT in Q2 2026 and held it in 1 quarter. The position peaked at $215K in Q2 2026. 118 funds tracked by Wall St. Rank hold COGT as of Q3 2026.

  • Wealth Enhancement Advisory Services reported no remaining Cogent Biosciences position as of Q3 2026 after selling out during the quarter.
  • Wealth Enhancement Advisory Services sold 5,541 Cogent Biosciences shares in Q3 2026, an estimated $215K.
  • Wealth Enhancement Advisory Services first reported a position in Cogent Biosciences in Q2 2026 and held it in 1 quarter.
  • Wealth Enhancement Advisory Services's Cogent Biosciences position peaked at $215K in Q2 2026.
  • 118 funds tracked by Wall St. Rank held Cogent Biosciences as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.